Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2019
SIETES contiene 92806 citas

 
 
 1 a 20 de 144 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
2. Cita con resumen
Ruggiero A, Ferrara P, Attinà G, Rizzo D, Riccardi C. Renal toxicity and chemotherapy in children with cancer. Br J Clin Pharmacol 2017;83:2605-14. [Ref.ID 102170]
3.Enlace a cita original Cita con resumen
Page II RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J, On behalf of the American Heart Association Clinical Pharmacology and Heart Failure and Trans- plantation Committees of the Council on Clini- cal Cardiology, Coun- cil on Cardiovascular Surgery and Anesthesia, Council on Cardio- vascular and Stroke Nursing, and Council on Quality of Care and Outcomes Research. Drugs that may cause or exacerbate heart failure. A scientific statement from the American Heart Association. Circulation 2016;134:9 de agosto. [Ref.ID 100519]
4. Cita con resumen
Anónimo. Traitements des cancers de l'enfance: effets indésirables à long terme. Prescrire 2015;35:348-52. [Ref.ID 99136]
5. Cita con resumen
Wise J. Benefits of trastuzumab outweight its harms, says Cochrane review. BMJ 2014;348:g3835. [Ref.ID 98034]
6. Cita con resumen
Anónimo. Atteintes des ongles d'origine médicamenteuse. Prescrire 2014;34:191-4. [Ref.ID 97362]
7. Cita con resumen
Anónimo. Pazopanib et sarcomes des tissus mous. Prescrire 2013;33:178. [Ref.ID 95025]
9.Tiene citas relacionadas Cita con resumen
Montastruc J-L, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and strenghts of the disproportionality analysis of identification of adverse drug reactions in a pharmacovigilance database. Br J Clin Pharmacol 2011;72:905-8. [Ref.ID 91873]
10. Cita con resumen
Gatesman ML, Smith TJ. The shortage of essential chemotherapy drugs in the United States. N Engl J Med 2011;365:1653-5. [Ref.ID 91589]
11.Tiene citas relacionadas
Hayes DF. Steady progress against HER2-positive breast cancer. N Engl J Med 2011;365:1336-8. [Ref.ID 91536]
12.Tiene citas relacionadas Cita con resumen
Slamon D, Eiermann W, Robert N, Pienkow T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu M-C, Sauter G, von Minchwitz G, Visco F, Bee V, Buyse M, Bendahmana B, Tabah-Fisch I, Lindsay M-A, Riva A, Crown J, for the Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273-83. [Ref.ID 91532]
13. Cita con resumen
Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O0Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 2011;305:1873-81. [Ref.ID 90795]
14.Tiene citas relacionadas
Martín M. Adjuvant docetaxel for node-negative breast cancer. Author/editor response. N Engl J Med 2011;364:977-8. [Ref.ID 90638]
15.Tiene citas relacionadas
Sanz A, del Valle ML. Adjuvant docetaxel for node-negative breast cancer. N Engl J Med 2011;364:977. [Ref.ID 90637]
16.Tiene citas relacionadas
Venniyoor A. Adjuvant docetaxel for node-negative breast cancer. N Engl J Med 2011;364:976. [Ref.ID 90636]
17.Tiene citas relacionadas Cita con resumen
Parker C, Waters R, Leighton C, Hancock J, Sutton R, Moorman AV, Ancliff P, Morgan M, Masurekar A, Goulden N, Green N, Révész T, Darbyshire P, Love S, Saha V. Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial. Lancet 2010;376:2009-17. [Ref.ID 89861]
18.Tiene citas relacionadas
Schrappe M. Mitoxantrone in first-relapse paediatric ALL: the ALL R3 trial. Lancet 2010;376:1968-70. [Ref.ID 89855]
19.
Swain SM, Jeong J-H, Wolmark N. Amenorrhea from breast cancer therapy - Not a matter of dose. N Engl J Med 2010;363:2268-70. [Ref.ID 89756]
20.Tiene citas relacionadas Cita con resumen
Martin M, Seguí MA, Antón A, Ruiz A, Ramos M, Adrover E, Aranda I, Rodríguez-Lescure A, Grobe R, Calvo L, Barnadas A, Isla D, Martínez del Prado P, Ruiz Borrego M, Zaluski J, Arcusa A, Muñoz M, López Vega JM, Mel JR, Munarriz B, Llorca C, Jara C, Alba E, Florián J, Li J, López García-Asenjo JA, Sáez A, Rios MJ, Almenar S, Peiró G, Lluch A, for the GEICAM 9805 Investigators. Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 2010;363:2200-10. [Ref.ID 89747]
Seleccionar todas
 
 1 a 20 de 144 siguiente >>